OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC

Report Publication Announcement • Mar 26, 2024

National Storage Mechanism | Additional information

RNS Number : 3425I

Oxford Cannabinoid Tech.Holdings

26 March 2024

Oxford Cannabinoid Technologies Holdings plc (OCT) have launched new video content with Doceo.

OCT is a pharmaceutical company developing prescription cannabinoid medicines for approval by global regulatory agencies and targeting the US$ multi-billion pain market. OCT aims to revolutionise drug development by utilising a diverse range of compounds, including proprietary cannabinoid derivatives, natural phytocannabinoids, and innovative new chemical entities (NCEs) that target the endocannabinoid system.

Clarissa Sowemimo-Coker, Chief Executive Officer, explains how the company is developing non-addictive, cannabinoid-based medicines. There is demand for alternatives from people living with debilitating pain conditions that are poorly served by current treatments.

[Video content removed for conversion]

For further information on Doceo please visit  www.doceo.tv  or contact the team on  info@doceo.tv

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABGGDXXUDDGSL